Global Hepatocellular Carcinoma (Nexavar & Miripla) Drug Sales 2017 - Pipeline Analysis and Market Forecast 2022 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Hepatocellular Carcinoma Drug Sales (Nexavar & Miripla), Pipeline Analysis and Global Market Forecast 2022" report to their offering.

The global hepatocellular carcinoma drug market is anticipated to witness a remarkable growth in the coming years. The report provides insights about the major drivers and challenges, along with the latest innovations in this industry. In addition, the report also highlights various opportunities for the growth of the Global Hepatocellular Carcinoma Market.

The report provides insights about the major drivers and challenges, along with the latest innovations in this industry. In addition, the report also highlights various opportunities for the growth of the Global Hepatocellular Carcinoma Market.

Key factors supporting the growth of the global hepatocellular carcinoma market include increasing incidences of chronic diseases like infection with hepatitis B or C virus, diabetes, obesity, non-alcoholic fatty liver diseases, and others. Moreover, the growing aging population, adoption of sedentary lifestyle, and increasing R&D investments are also adding up to the growth of global hepatocellular carcinoma market. However, drug failures in pipeline and stringent regulatory challenges are expected to hamper the growth of the global hepatocellular carcinoma drug market.

Furthermore, in this report we have structured the information regarding hepatocellular drugs at various stages of clinical development, totaling to over 350 drugs that are under research or in collaboration and those individually being developed by companies. Out of which, 102 drugs are being developed by industries and rest of the drugs are developed by the research collaborations. The report also provides the segmentation of hepatocellular carcinoma drugs under clinical development on the basis of clinical phase.

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. Hepatocellular Carcinoma- An Introduction

4. Market Dynamics

5. Global Hepatocellular Carcinoma Drug Market Outlook 2022

6. Global Hepatocellular Carcinoma Drug Pipeline Analysis

7. Market Segment by Geography

8. Company Profiles

  • Alnylam Pharmaceuticals, Inc.
  • ArQule, Inc.
  • Bayer AG
  • Bristol-Mayers Squibb
  • Celsion, Inc.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • Pfizer Inc.
  • Polaris Pharmaceuticals, Inc. (PPI)
  • Teva Pharmaceutical Industries Ltd.

For more information about this report visit http://www.researchandmarkets.com/research/ss22n9/global

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs , Oncology Drugs , Kidney Cancer Drugs , Thyroid Cancer Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs , Oncology Drugs , Kidney Cancer Drugs , Thyroid Cancer Drugs